Study Evaluating DVS-233 in Adult Outpatients With Major Depressive Disorder

• Status: Completed
• Trial end date: 2004-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Primary: To compare the antidepressant efficacy and safety of subjects receiving DVS-233 SR versus subjects receiving placebo.

Secondary: To assess the response of subjects receiving DVS-233 SR for the clinical global evaluation, functionality, general well-being, pain, and remission (Hamilton Psychiatric Rating Scale for Depression, 17-item [HAM-D17] < 7) versus those subjects receiving placebo.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Criteria

Inclusion Criteria:

• Subjects must have a primary diagnosis of major depressive disorder (MDD)

• Depressive symptoms for at least 30 days prior to the screening visit

• Minimum screening and study day -1 (baseline) scores of 20 on the Hamilton Psychiatric Rating Scale for Depression (HAM D17)

Exclusion Criteria:

• Treatment with DVS-233 SR at any time in the past

• Treatment with venlafaxine (immediate release [IR] or extended release [ER]) within 90 days of study day 1

• Known hypersensitivity to venlafaxine (IR or ER)